The Food and Drug Administration is reviewing the safety of a class of drugs called tumor necrosis factor blockers, currently used to treat autoimmune conditions such as adult and juvenile rheumatoid arthritis and Crohn's disease. Among the concerns is whether these medicines are linked to cancer risk, particularly lymphoma in kids and young adults. The FDA is looking into about 30 reports of cancer among younger people submitted between 1998—when the first TNF blocker was approved—through April of this year. The drugs are also tied to an increased risk of infection.
No comments:
Post a Comment